Key result
Milvexian shows dose-dependent VTE prevention without increasing bleeding risk in phase II trials.
Why the study?
Direct oral anticoagulants have a dose-dependent increased bleeding risk that limits their use in certain populations, creating an unmet clinical need.
Answers are grounded in this paper and cite their sources.
Milvexian is an emerging oral factor XIa inhibitor that may offer effective anticoagulation without the dose-dependent bleeding risks associated with current direct oral anticoagulants.
Direct oral anticoagulants have a dose-dependent increased bleeding risk which limits use in certain populations. Studies in both animals and humans with inherited variations in factor XI levels provide a theoretical basis for a drug target capable of addressing current unmet needs. Milvexian is an oral factor XIa inhibitor that has the potential to provide robust anticoagulant effect without increased bleeding compared with current standard of care. Several key studies in the preclinical, phase I, and phase II stages have reported promising safety data in venous thromboembolism and stroke prevention without compromising hemostasis. The planned phase III trials will examine the efficacy of milvexian for prevention of thrombotic events in patients with acute stroke, acute coronary syndrome, and atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Parsa et al. (2024) conducted a review in Thromboembolism. Milvexian was evaluated. Milvexian, an oral factor XIa inhibitor, demonstrated dose-dependent prevention of venous thromboembolism without increasing bleeding risk in phase II trials, supporting its ongoing evaluation in large-scale phase III trials.
Synapse has enriched 10 related papers. Consider them for comparative context: